In part 5, the conclusion of this Exclusive Interview, Dr. Yehuda Handelsman talks with Diabetes in Control Publisher Steve Freed during the AACE 2018 convention in Boston, MA about possible future breakthroughs in diabetes devices and therapies.
Yehuda Handelsman, MD, FACP, FNLA, MACE is a past president of the American College of Endocrinology and Medical Director of the Metabolic Institute of America in Tarzana, CA.
Transcript of this video segment:
Freed: So, if you look into the future, you’re involved in a lot of studies… do you see any kind of breakthroughs in science for diabetes?
Handelsman: I do not think in science. What I am seeing is that we have glucose monitors – we now are going to get an implantable glucose monitor approved most likely. If you are going to have an implantable monitor for three months, this is a (brain to put a closed loop that we call and we’re allowed to have an independent system implanted. I can see that happening in three to five years. I think that would be a huge breakthrough. Another interesting breakthrough is to look at creating some cell lines that will transfer from STEM lines into beta cells and we are seeing at least two independent slides. It is still a bit too early but right now, I am seeing that happen in front of my own eyes. Until now, we needed to get it from a lot of pancreases to get beta cells to be good for a couple of years. Once we get limitless beta cells and everyone works to protect them from the immune system, it is another breakthrough.
Freed: Well, I want to thank you for your time. Enjoy the rest of your time here in Boston and I thank you once again for all of this great information.
Handelsman: Thank you for having me!